Holly J Pederson1, Dharmesh Gopalakrishnan2, Ryan Noss3, Courtney Yanda4, Charis Eng3, Stephen R Grobmyer5. 1. Breast Services Section, Department of General Surgery, Cleveland Clinic, Cleveland, OH; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH. 2. Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH. 3. Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH. 4. Breast Services Section, Department of General Surgery, Cleveland Clinic, Cleveland, OH. 5. Breast Services Section, Department of General Surgery, Cleveland Clinic, Cleveland, OH. Electronic address: grobmys@ccf.org.
Abstract
BACKGROUND: With the advent of multigene panel testing for breast cancer patients, germline mutations with unknown association with cancer risk, known as variants of uncertain significance (VUS), are being increasingly identified. Some studies have shown higher rates of contralateral prophylactic mastectomies (CPM) in these patients, despite lack of evidence to support this intervention. We analyzed surgical choices in patients who were identified to have VUS. STUDY DESIGN: A retrospective review was performed of patients with triple-negative breast cancer treated at a single institution after multigene panel tests became available (September 1, 2013 to February 28, 2017). Rates of genetic testing, results of testing, and surgical decision making were evaluated. Chi-square or Fisher's exact test was used to compare categorical variables. A p value <0.05 was considered statistically significant. RESULTS: There were 477 triple-negative breast cancer patients identified; 331 met established criteria for genetic testing and 226 (68.3%) underwent genetic testing (multigene panel, n = 130 and BRCA1/2 testing, n = 96). All of them received risk-appropriate genetic counseling and follow-up. Of these, 29 (12.8%) patients had pathogenic mutations in BRCA1/2 or PALB2 (Mut+), 42 (18.6%) had VUS (VUS+), and 155 (68.6%) had no mutations identified (Mut-). Variants of uncertain significance in 6 of 42 patients (14.3%) were later reclassified as normal variants. Eighty-eight percent of Mut+ patients underwent CPM compared with 20.1% of Mut- and 21.4% of VUS+ patients (p < 0.001 for both). Rates of CPM were not significantly different between VUS+ and Mut- (p = 0.37). Multigene panel testing detected pathogenic mutations in non-breast cancer-associated genes in 6 patients, with significant management implications. CONCLUSIONS: When combined with risk-appropriate genetic counseling, detection of VUS did not lead to excessive CPM in this cohort of triple-negative breast cancer patients. Furthermore, panel testing detected mutations in non-breast cancer-associated genes, which had significant implications on management and outcomes.
BACKGROUND: With the advent of multigene panel testing for breast cancerpatients, germline mutations with unknown association with cancer risk, known as variants of uncertain significance (VUS), are being increasingly identified. Some studies have shown higher rates of contralateral prophylactic mastectomies (CPM) in these patients, despite lack of evidence to support this intervention. We analyzed surgical choices in patients who were identified to have VUS. STUDY DESIGN: A retrospective review was performed of patients with triple-negative breast cancer treated at a single institution after multigene panel tests became available (September 1, 2013 to February 28, 2017). Rates of genetic testing, results of testing, and surgical decision making were evaluated. Chi-square or Fisher's exact test was used to compare categorical variables. A p value <0.05 was considered statistically significant. RESULTS: There were 477 triple-negative breast cancerpatients identified; 331 met established criteria for genetic testing and 226 (68.3%) underwent genetic testing (multigene panel, n = 130 and BRCA1/2 testing, n = 96). All of them received risk-appropriate genetic counseling and follow-up. Of these, 29 (12.8%) patients had pathogenic mutations in BRCA1/2 or PALB2 (Mut+), 42 (18.6%) had VUS (VUS+), and 155 (68.6%) had no mutations identified (Mut-). Variants of uncertain significance in 6 of 42 patients (14.3%) were later reclassified as normal variants. Eighty-eight percent of Mut+ patients underwent CPM compared with 20.1% of Mut- and 21.4% of VUS+ patients (p < 0.001 for both). Rates of CPM were not significantly different between VUS+ and Mut- (p = 0.37). Multigene panel testing detected pathogenic mutations in non-breast cancer-associated genes in 6 patients, with significant management implications. CONCLUSIONS: When combined with risk-appropriate genetic counseling, detection of VUS did not lead to excessive CPM in this cohort of triple-negative breast cancerpatients. Furthermore, panel testing detected mutations in non-breast cancer-associated genes, which had significant implications on management and outcomes.
Authors: Brittany L Murphy; Min Yi; Banu K Arun; Angelica M Gutierrez Barrera; Isabelle Bedrosian Journal: Ann Surg Oncol Date: 2020-07-27 Impact factor: 5.344
Authors: Shenin A Dettwyler; Darcy L Thull; Priscilla F McAuliffe; Jennifer G Steiman; Ronald R Johnson; Emilia J Diego; Phuong L Mai Journal: Breast Cancer Res Treat Date: 2022-05-21 Impact factor: 4.872
Authors: Mara Tynan; Beth N Peshkin; Claudine Isaacs; Shawna Willey; Heiddis B Valdimarsdottir; Rachel Nusbaum; Gillian Hooker; Suzanne C O'Neill; Lina Jandorf; Scott P Kelly; Jessica Heinzmann; Sarah Kelleher; Elizabeth Poggi; Marc D Schwartz Journal: Breast Cancer Res Treat Date: 2020-01-01 Impact factor: 4.872